Pfizer stops OTC Lipitor trial
Pfizer will not be manufacturing an over-the-counter version of atorvastatin (Lipitor) after the company terminated its clinical trial program, Bloomberg reports. Since losing patent protection in 2011, sales of atorvastatin have decreased from more than $10 billion per year to $2.06 billion in 2014.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.